Baxter (BAX) Tops Q1 EPS by 10c

Baxter (NYSE: BAX) reported Q1 EPS of $0.82, $0.10 better than the analyst estimate of $0.72. Revenue for the quarter came in at $2.8 billion versus the consensus estimate of $2.75 billion.

2020 Financial Outlook

Given the high-degree of uncertainty around the potential financial impacts from the COVID-19 pandemic on Baxter’s operations, the company is not in a position to provide guidance for the second quarter or full-year 2020 at this time. As the quarter progresses, Baxter may provide additional information regarding its operations as appropriate.

For earnings history and earnings-related data on Baxter (BAX) click here.

You May Also Be Interested In

• Tesla plans 'flying' Roadster stunt at SpaceX Texas site as early as August
• Edible Garden AG (EDBL) Reports Q2 Loss of $18.79
• Neumora Therapeutics, Inc. (NMRA) Tops Q2 EPS by 4c